Can You Stop Immunotherapy After Two Years?

For many patients whose disease has responded well over roughly two years of maintenance dosing, stopping on schedule is generally considered safe and reflects the approach set out in NCCN and ASCO guidance. It's a clinician-led decision confirmed with imaging and bloodwork at your planned review — not something that applies automatically just because two years have passed on the calendar.

In some individual cases, continuing a little longer is what your oncologist recommends instead — for example, if a scan shows a partial response that is still visibly improving. Stopping at two years is the common path on many protocols, but it is one option your team weighs against continuing, not a rule applied the same way to everyone.

This page explains the framework your oncology team actually uses. It is general information, not a recommendation for your specific case — that decision belongs to you and your treating oncologist, made from your own scans.

There is no single number that applies to every patient, and no oncologist can guarantee an outcome either way — relapse risk after stopping depends on your cancer type, how completely the disease responded, and individual biology. Published follow-up cited by NCCN and ASCO shows many patients who stop on schedule continue to do well for a long period afterward, while a smaller group does relapse and is re-evaluated at that point.

This is exactly why follow-up scans and check-ins continue on the same schedule after stopping as they did during treatment — the plan isn't "stop and forget," it's "stop and keep watching," specifically so that any change is caught early rather than found late.

• Depth of response — a complete response on scans generally carries a more favourable outlook than a partial response, though neither is a guarantee.
• Cancer type and original stage — how a specific cancer type typically behaves after stopping is part of published guidance your oncologist draws on.
• Duration already completed — patients who completed the full planned course are assessed differently from those stopping earlier for side effects.
• Biomarker status at diagnosis — some biomarker patterns are associated with more durable responses in published data, discussed with you individually.

In many cases, yes. If a follow-up scan after stopping shows the disease has returned, restarting the same class of checkpoint inhibitor immunotherapy — or moving to a different treatment approach — is a recognised option your oncology team considers, based on how the disease responded the first time and what the new scans show.

This possibility is normally discussed as part of the original stopping plan, not treated as an afterthought if relapse happens. It's one of the main reasons follow-up visits continue on schedule after stopping rather than tapering off — catching a relapse early keeps restarting options open.

Bring every prior scan report to this review, not just the most recent one — your team is looking at the trend across your treatment, not a single snapshot. This is also the point where cost, fatigue, and how you're doing day-to-day are worth raising directly, alongside the clinical picture.

• What Happens If You Stop Immunotherapy Early? — if you're weighing stopping before the two-year mark rather than at it, the considerations are different.
• Making the Decision to Stop: A Framework for Families — a fuller walkthrough of how to have this conversation as a family, alongside your oncology team.
• Treatment-Free Remission: Staying Well After Stopping — what the follow-up period actually looks like once you've stopped on schedule.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through immunotherapy, from candidacy to stopping and follow-up care.

This page is for general information and does not replace a consultation. Whether to stop, continue, or restart immunotherapy is a decision for you and your treating oncologist, based on your own scans and history.

The two-year question comes up for almost every long-term patient

Understanding how the stopping decision actually gets made is the first step to a confident, clinician-led conversation about your own timeline.